In a late-stage CTCL mouse model, intervention with miR-150 targeting CCR6 effectively downregulated the expression of CCL20, disrupted this autocrine loop, significantly inhibited CTCL metastasis to distant organs, and thus, extended the survival of the model mice [45,67]. Here, CCR6 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.